Jacob Corn

Jacob Corn has been in the field of genome biology since 2002. Jacob began their career as a Research Associate at The J. David Gladstone Institutes in 2001. Jacob then went on to become a Graduate Student Researcher at UC Berkeley in 2002. In 2008, they became a Jane Coffin Childs Senior Fellow at the University of Washington, where they conducted computational modeling and de novo design of protein-protein interactions. In 2010, they joined Genentech as a Scientist (group leader), where they led a group of experimental and computational biologists and supervised a core lab focused on macromolecular display technologies. In 2014, they became the Scientific Director of the Innovative Genomics Institute, a joint venture between the University of California Berkeley and the University of California San Francisco, where they set the overall scientific and organizational strategy. Jacob also served as an Assistant Adjunct Professor at UC Berkeley in 2014. In 2017, they co-founded Spotlight Therapeutics. Currently, they are a Professor of Genome Biology at ETH Zürich, which they have been since 2018.

Jacob Corn completed their B.Sc. in Biology from the University of Puget Sound in 2001. Jacob then went on to pursue a Ph.D. in Biochemistry from the University of California, Berkeley, which they completed in 2008.